Immunogen, Inc.

NASDAQ:IMGN  
3.58
+0.05 (+1.42%)
Other Pre-Announcement

Immunogen Reports Recent Progress And First Quarter 2022 Financial Results

Published: 05/06/2022 10:46 GMT
Immunogen, Inc. (IMGN) - Immunogen Reports Recent Progress and First Quarter 2022 Financial Results.
Immunogen Inc - Top-line Data From Confirmatory Mirasol Trial Now Expected in Early 2023 Based on Recent Reforecast of Projected Pfs Events.
Immunogen Inc - Total Revenues Were $38.1 Million for Quarter Ended March 31, 2022 Compared to $15.7 Million.
Immunogen Inc Qtrly Loss per Share $0.10.
Immunogen Inc - Immunogen's Financial Guidance for 2022 Remains Unchanged.